Abstract Details

Title Multicenter Registry for Venous Sinus Stenting in IIH

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) S22 - Innovations in Cerebrovascular Therapy (4:18 PM-4:30 PM)

Poster/Presentation
Number 005

Objective

To examine the demographics and clinical outcomes of patients who underwent cerebral venous sinus stenting (VSS) for medically refractory idiopathic intracranial hypertension (IIH) across two tertiary hospitals in the United States.

Background IIH is characterized by increased intracranial pressure, commonly presenting with headaches, visual disturbances, and pulsatile tinnitus. Traditional surgical intervention involves cerebrospinal fluid diversion, but many patients require shunt revision. While cerebral VSS is emerging as an alternative, large multicenter studies, particularly those identifying predictors for repeat stenting, remain limited.

Design/Methods A retrospective analysis was conducted on IIH patients treated with VSS at two tertiary hospitals from 2012 to 2024. Demographics, baseline clinical characteristics, and clinical outcomes were evaluated for up to 12 months post-treatment.

Results Among 168 IIH patients (mean age 39 years), 92.3% were female (n=155). The mean pressure gradient across the stenosis decreased significantly from 14.96 pre-stenting to 1.28 mmHg post-stenting (P<0.001). Headaches (86.4%) and pulsatile tinnitus (69.7%) improved post-stenting. Papilledema, using Frisen grading, decreased significantly in both eyes from 68.9% to 34% post-stenting (P<0.001). Repeat stenting occurred in 18 patients (10.7%) and was significantly more likely in those with stent adjacent stenosis (P<0.001). Initial tinnitus (P=0.03), as the primary concern among symptoms, was a significant predictor of requiring repeat stenting. Higher BMI (P=0.20) and left-sided venous sinus stenosis (P=0.12) were associated with repeat stenting but were not statistically significant. Stent type did not have a significant impact on repeat stenting (P=0.27).

Conclusions

Our preliminary data suggest that VSS is effective for medically refractory IIH and carries a low risk of repeat stenting. We hypothesize that a higher BMI and left-sided venous sinus stenosis may also be predictors for requiring repeat stenting. Our study is ongoing, and we will confirm these findings upon its completion.

Authors/Disclosures
Tara Samiee, DO (University of Kansas Medical Center) PRESENTER	Dr. Samiee has nothing to disclose.
Anqi Luo, MD	Dr. Luo has nothing to disclose.
Sujani Bandela, MD	Dr. Bandela has nothing to disclose.
Alibay Jafarli, MD	Dr. Jafarli has nothing to disclose.
Sivani Lingam, MBBS (University of Kansas Medical Center)	Dr. Lingam has nothing to disclose.
Aspin R. Denson	Mr. Denson has nothing to disclose.
Iheanyi Amadi, MD	Mr. Amadi has nothing to disclose.
Anna Speckin	Ms. Speckin has nothing to disclose.
Michael Gaub, MD	Dr. Gaub has nothing to disclose.
Sai Kumar Reddy Pasya, MD, MBBS	Dr. Pasya has nothing to disclose.
William Lynch III	Mr. Lynch has nothing to disclose.
Gretchel Gealogo Brown (UT Health San Antonio)	Gretchel Gealogo Brown has nothing to disclose.
Michael G. Abraham, MD (The University of Kansas Health System)	Dr. Abraham has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stryker Neurovascular.
Lee Birnbaum, MD	Dr. Birnbaum has nothing to disclose.

��ɫ��

��ɫ��